Lupin PharmaPharma firm, Lupin Limited, today said it is looking to acquire a company in the injectibles space in Japan.

We are looking to acquire a company in the next 6-10 months," Lupin Limited's President (Finance and Planning), S Ramesh, told pharmaquest.biz on the sidelines of a seminar here.

He did not divulge any further details. On Lupin Pharmaceuticals, Ramesh said it would pump in Rs 500-crore in capacity expansion this fiscal. Lupin Pharmaceuticals is the US wholly-owned subsidiary of Lupin Limited.

"We will invest the same amount in the next financial year also," he said.

The company expects a 20-21 per cent increase in revenue in the Indian market and a 23 per cent increase in the Japanese market in the next financial year, he said.

"Japan is a good market and we expect at least a 23 per cent revenue-increase from there," he added.

Lupin Limited was also expecting to resolve its issue with the US Food and Drug Administration, involving some deficiencies found by the US regulator in one of its facilities, to get resolved soon.

"We believe it will get resolved before March 2010," Ramesh said.